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Abstract 
As the world’s primary morbidity factor, depression has a considerable impact on both an 
individual as well as a societal level. It is a complex and multifactorial mental health disorder, 
one whose pathophysiology is not yet fully understood. Despite their discovery several 
decades ago, classical antidepressants have been shown to provide limited benefits against 
this condition, yet no major enhancement since has been proven to treat major depressive 
disorder more efficiently. 
However, substances such as ketamine and psychedelics (5-HT2AR agonists) have recently 
shown promising results and even received the grade of « Breakthrough Therapy » for this 
indication. The accurate mechanisms of action underlying the efficacy of these substances are 
still to be defined, but some similarities appear to be shared on different levels across these 
substances. These include their structural, functional and behavioral plasticity promoting 
abilities, as well as their capacity to promote Brain-Derived Neurotrophic Factor 
overexpression, which seems to constitute a key element underlying their immediate and 
long-lasting action. 
From this observation, the present review aims to examine and connect the pharmacological 
pathways involved in these therapies to the neurobiological, cognitive and psychological 
responses that could be shared by both 5-HT2AR agonists and NMDA antagonists. It is 
suggested that BNDF overexpression resulting from mTOR activation would mediate both 
structural and functional plasticity, resulting in connectivity changes among high-level 
cognitive networks such as the Default Mode Network, finally leading to an increased and 
long-lasting psychological flexibility. 
Connecting these pieces of evidence could provide interesting insights about their precise 
mechanisms of action and help researchers to develop biomarkers for antidepressant response 
in the future, contributing at the same time to getting a clearer idea concerning several 
components of MDD. If the hypotheses suggested in this review are verified by further trials, 
they could also constitute a starting point to developing safer and more efficient 
antidepressants, as well as provide information about the interactions that exist between 
different neurotransmitters systems. 
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Abbreviation list  
5-HIAA : 5HydroxyIndolAcétic acid 
5-HT : Serotonin 
AAQ-2 : Acceptance and Action Questionnaire 
ACTH  : AdrenoCorticoTrophic Hormone  
ATU : temporary authorization of use 
BDNF : Brain-Derived Neurotrophic Factor 
BBB : blood brain barrier 
BOLD : blood-oxygen-level dependent 
CIA : Central Intelligence Agency  
CIM-10 : international classification of diseases 
CRH : Corticotrophin Releasing Hormone 
CRP : C-reactive Protein 
DAS : Death Anxiety Scale 
DASS-21 : Depression, Anxiety and Stress Scales 
DHF : dihydroxyflavone 
DMN : Default Mode Network 
DMT : Dimethyltryptamine 
DMSO : diméthylsulfoxyde 
DOI : 2,5-Dimethoxy-4-iodoamphetamine 
Dr : Doctor 
DSM : Diagnostic and Statistical Manual of Mental Disorders 
DTS : Death Transcendance Scale 
ECT : Electroconvulsive Therapy 
FDA : Food and Drug Administration 
GRID-HAM-D/A : GRID-Hamilton Depression/Anxiety Rating Scale 
GC : GlucoCorticoides  
HADS : Hospital Anxiety and Depression Scale 
IL : InterLeukin 
MAOI : Monoamine oxidase inhibitors 
MDD : major depresive disorder 
MRI : Magnetic Resonnance Imagery  
fMRI : Functionnal-MRI 
RS-fMRI : FMRI during resting state 
CSF : cerebrospinal fluid 
LSD : Lysergic Acid Diethylamide 
LTP : Long Term Potentiation  
MEQ30 : Mystical Experience Questionnaire 
mPFC : Medial Prefrontal Cortex 
mTOR : mechanistic Target Of Rapamycin 
NMDA : N-méthyl-D-aspartate 
WHO : World Health Organisation 
PCC : Posterior Cingulate Cortex 
PFC : PreFrontal Cortex 
PIQ : Psychological Insight Questionnaire 
CNS : Central Nervous system 
STAI : State Trait Inventory Anxiety 
tDCS : Transcranial Direct Current Stimulation 
TrkB : Tyrosine Receptor Kinase B 
TNF alpha : Tumor Necrosis Factor alpha  
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Introduction: state of the art of major depressive disorder and 
opportunities opened by neuroplasticity 
According to the WHO, depression represents the first morbidity factor in the world and 
would affect 300 million people (OMS, 2008). 
This mood disorder is included in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) and the International Classification of Diseases (ICD-10) (OMS, 2008). 
The consequences of this disease are serious and can become dramatic, leading to weakened 
social relationships and incapacitated professional life. 
Depression is also correlated to metabolic, cardiovascular and infectious diseases, and 
represents the first suicide risk factor. Suicide rates increase 21-fold for patients with major 
depressive disorder (Olié et Mouren, 2014). 
Classic antidepressant treatments such as tricyclic antidepressants, monoamine oxidase 
inhibitors (MAOI), and serotonin recapture inhibitors have all been developed on the basis of 
the monoaminergic hypothesis of depression, first introduced in the early 70s. It hypothesizes 
that an abnormally low monoaminergic activity in the brain would underlie a major 
depressive episode and that the above-mentioned anti-depressants would be effective in 
balancing that deficit. 
This theory relies on the argument that a reduced amount of serotonin metabolites has been 
observed in the cerebrospinal fluid (CSF) of depressed patients without antidepressant 
treatment by Ashcroft and his team in the 50’s. 
Reduced concentrations of Serotonin (5-HT) and 5HydroxyIndolAcétic acid (5-HIAA) were 
also observed postmortem in depressed and suicide victims’ brains. Additionally, patients with 
MDD presented lowered plasmatic concentrations of tryptophan, a serotonin precursor 
(Owens and Nemeroff, 1994). 
Unfortunately, this hypothesis alone cannot be taken as a model of depression, and the large 
STAR*D study, conducted in 2014 shown that fifty percent of depressive patients are 
considered to be treatment-resistant. 
Depression is nowadays considered to be a complex, multifactorial disease that must be 
modelized in the light of multiple complementary and imbricated hypotheses: Firstly, 
depression seems to have a strong hereditary component, according to studies conducted in 
twins, which show a significantly stronger prevalence of this disease in individuals that share 
the same genetic heritage (Su et al., 2009, Sullivan et al., 2000). 
Among the theories aiming to explain this pathology, one of the most studied recently is the 
inflammatory hypothesis of depression, based on the neuroinflammation phenomenon. 
Neuroinflammation depends on to two major mechanisms: a central mechanism that involves 
neuronal and astroglial production of cytokines (Fleshner et al., 2017; Wohleb et al., 2016), 
and a peripheral mechanism, which enables cytokines to reach the CNS either through active 
transport or passive diffusion from one side to another of the BBB (blood brain barrier) (Quan 
and Banks 2007). 
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Peripheral cytokines can also act on the CNS via the vagus nerve (CN X) activation –
involving intestinal microbiota– and through the entry of activated peripheral monocytes in 
the CNS (Krishnadas and Cavanagh 2012). 
The inflammatory hypothesis of depression is reinforced by several arguments: first, the 
observable co-morbidity between depression and diseases related to the immune system 
(especially cardiovascular and auto-immune diseases; Halaris 2017, Pryce et al., 2017), but 
also the observable modulation of cytokines rates in depressive disorder, such as increased 
rates of TNF alpha, IL-6 and CRP (Huang et al., 2018; Zhang et al., 2018; Zou et al., 2018; 
Danner et al., 2003; Dowlati et al., 2010). These increases seem to be correlated to the 
severity of the depressive episode (Zou et al., 2018). 
Significantly higher rates of several pro-inflammatory factors, such as TNF-alpha and IL-2 
have been reported in patients that have committed a suicide attempt (Janelidze et al., 2011, 
Pandey et al., 2012). 
In addition, this theory is supported by the fact that administrating exogenous cytokines (for 
example, giving interferon to patients with cancer) can induce depressive symptoms 
(Krishnadas and Cavanagh 2012, Capuron and Miller 2011), and that anti-inflammatory 
treatments and anti-cytokines can have a positive impact on mood (Liu et al., 2017; Raison 
2017; Köhler et al., 2014; Kappelmann et al., 2016). 
The implication of intestinal microbiota in depression has also been a major point of interest 
recently. 
A microbiota is represented by the commensal (nonpathogenic) flora, constituted of 
microorganisms in a specific environment. More specifically, intestinal microbiota represents 
the largest human microbiota, weighing around 2kg, containing 2 to 10-fold more cells than 
the total number of cells constituting the human body. 
This microbiota has a role in digestion, ensures proper functioning of the epithelium, and 
modulates the intestinal immune system (Doré et al., 2017). 
According to Bailey, 2007, the intestinal microbiota could be implicated in MDD when 
modification of the homeostatic interaction between the microbiota and its host occurs, under 
the influence of stress –especially by means of glucocorticoids–. This phenomenon generates 
an increase in microbiota’s activity, causing oxidative reactions, and resulting in an increase 
in inflammation and therefore in increased cytokines productions. 
Several studies have shown that the rates of some bacterial species constituting the microbiota 
are significantly altered in patients with MDD when compared to controls (Lin et al., 2017; 
Aizawa et al., 2016). Accordingly, the administration of probiotics might significantly 
decrease depressive symptoms, according to a meta-analysis by Akkasheh et al. conducted in 
2016.  
Lastly, the hypothalamic-pituitary-adrenal (HPA) axis hypothesis relies on the pre-existing 
link between chronic stress and depression. This theory takes place at a central position in the 
pathophysiology of depressive disorder, interacting directly with the inflammatory and the 
microbiota arguments, but also with the monoaminergic hypothesis. 
Under normal conditions, stress leads to CRH (Corticotrophin Releasing Hormone) and 
vasopressin release from the hypothalamus, leading to ACTH (adrenocorticotrophic hormone) 
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release from the pituitary gland, finally leading to glucocorticoid (especially cortisol) 
production by the adrenal gland.  
Glucocorticoids act both at the peripheral and the central level, causing a disturbance in 
neuronal survival, neurogenesis, memorization, and emotional appreciation (Herbert et al., 
2006; Pariante and Lightman 2008; Nicolaides et al., 2015). 
In standard conditions, this system is subject to feedback: a large amount of GC causes a 
decrease in CRH and vasopressin release, ensuring homeostasis. In depression, this feedback 
system would be dysfunctional due to chronic stress exposure. 
In this situation, there is a decrease in monoamine levels (including serotonin) due to a 
redirection of tryptophan metabolism towards kynurenines’ production (under the action of 
cortisol activating Nf-kB factor) also leading to an increase in cytokines levels (Miller et al., 
2009). 
To support this hypothesis, it is important to note that abnormally high cortisol levels are 
found in saliva, plasma and urine of depressed patients, although these results are inconsistent 
(Nemeroff et Vale 2005). 
Furthermore, neurotrophic factors involved in neuronal and synaptic plasticity such as BDNF 
(Brain-Derived Neurotrophic Factor), have a preponderant role within this last hypothesis: 
It has been demonstrated that stress induces a decrease in the expression of BDNF; for 
example, in the dentate gyrus and hippocampus more generally, in animals (Smith 1996) and 
that a decrease in plasmatic BDNF, correlated to central concentration, is observed in 
depressed patients. Conversely, the majority of classic antidepressants induce an increase in 
BDNF concentrations, making it possible to reverse the effects of stress involved in 
depression (Nibuya et al., 1996). 
Moreover, overexpression of cortical BDNF has also been observed in patients that were 
responsive to antidepressant treatments (Shimizu et al., 2003). 
  
These elements suggest that there is a reachable therapeutic path involving BDNF and the 
neuronal and synaptic plasticity it promotes. 
According to this perspective, it is useful to mention that innovative antidepressant 
treatments, involving various mechanisms of action, share the capacity to induce BDNF 
overexpression and promote neuronal plasticity, which seems to be a decisive and necessary 
factor for their long-term efficacy: 
Ketamine, a molecule with anesthetic and dissociative proprieties, whose action is lying 
principally on glutamate NMDA-R antagonism, has recently received FDA approval for its 
use against depression and also has a Temporary Authorization of Use in France and other 
European countries for the same application (FDA, 2019). 
Its long-term efficacy seems to rely on the BDNF overexpression that it provokes through 
modulation of glutamatergic system and on its ability to promote neuronal plasticity, which 
results from this overexpression (Woelfer et al., 2019). However, the exact mechanisms 
underlying the efficacy of this molecule remain unclear (Yang et al., 2019). 
6
BAHI Camile, 2020
Psychedelics, a pharmacological class defined by their 5-HT2A receptor agonist properties 
and including hallucinogenic molecules such as lysergic acid diethylamide (LSD), psilocybin, 
N,N-dimethyltryptamine (DMT) or mescaline, are also studied for their application in 
depression. Psilocybin recently received the grade of “breakthrough therapy” from the FDA in 
this indication. These substances reveal a promising efficacy in depression, including 
treatment-resistant forms. (Griffiths, 2016; Ross, 2016; Carhart-Harris et al., 2016; see Bahi, 
2018; Reiche et al., 2018 for reviews). 
These molecules are of particular interest for several reasons: first of all, they are effective 
against depression in an immediate and lasting way over more than 6 months after a single 
dose, they also cause a BDNF overexpression (which seems to be a key element of their 
efficacy) and have a strong specificity of action on the 5HT2A receptors, a serotonin receptor 
subtype located mainly on layer V pyramidal glutamatergic neurons (Carhart-Harris and Nutt, 
2017, Vollenweider and Kometer, 2010). Moreover, their therapeutic and subjective effects 
are completely blocked by administrating an antagonist of these specific receptors (Preller et 
al., 2019; Pitts et al., 2017). 
In addition, although some 5-HT2A antagonists (such as mirtazapine) have a positive 
outcome on the symptoms of depression, no pure 5-HT2A-R antagonist has shown any 
efficacy in this pathology (Ebdrup et al., 2011). 
This suggests that the efficacy of these antagonists is dependent on other associated 
pharmacological mechanisms –blocking 5HT2A-R could facilitate agonism on 5HT1A 
postsynaptic receptor– and their sedative effect that contributes to reduce stress (Idzikowski et 
al., 1987; Teegarden et al., 2008; Vanover and Davis, 2010). 
These specificities place 5HT2A-R agonists in an interesting position for studying 
interactions between the serotoninergic system (involved in the efficacy of most anti-
depressive therapies) and other neurotransmitters systems such as glutamatergic system, 
whose involvement in neuroplasticity through the BDNF is now well established (Cohen-
Cory et al., 2010). 
An interesting model that has been developed recently implies that an increase in structural 
neural plasticity accompanied by changes in functional connectivity could be correlated to an 
increase in psychological flexibility in depressed patients. Given that MDD is characterized 
by mental rigidity and a pessimistic vision of the self and the world, restoring the capacity for 
action and active coping in patients would play a decisive role in the efficacy of these 
substances against depression (Carhart-Harris and Nutt, 2017; Davis et al., 2020). 
Studying the link between the systems exposed in this model could not only provide tangible 
arguments in favor of this model but also give the possibility to develop specific therapies 
targeted on the identified neurobiological mechanisms. It could also open new ways to 
develop reliable biomarkers to monitor the response to these therapies, which is currently 
lacking in MDD and generally in psychiatry. 
Accordingly, this review will focus on psychedelics by exploring their mechanism of action, 
aiming to connect pieces of evidence that support the exposed model both at a 
psychopharmacological, cognitive and psychological level. 
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Psychedelics in depression: an effective therapeutic class and a 
tool for understanding plasticity 
A brief history of psychedelics 
Psychedelics stricto sensu, characterized by their 5-HT2AR agonist properties and their 
hallucinogenic effect, are present in natural sources and used since immemorial times by 
different cultures around the world. 
Indeed, vestiges dedicated to the “mushroom god” have been found in Central America, 
dating from the year 1000 to 500 BC, a statue of a deity holding “sacred” plants in his hands, 
including Psilocybin mushrooms, dating from the 16th century was also found in Mexico and 
other vestiges related to Psychedelics were discovered around the world (Schultes, Hoffman, 
1992). 
It is only later, in 1943, following the LSD discovery by the chemist and researcher Albert 
Hofmann for Sandoz pharmaceuticals, that psychedelic properties began to receive interest 
from the scientific community. Later, in the 1950’s, Richard Evans Shultes returns from 
Central America, bringing Psilocybin mushrooms specimens to the Harvard herbarium. 
Hofmann then isolates the chemical compound called psilocybin in 1958 and synthesizes it in 
1959. Sandoz Laboratories decides to submit these two interesting substances to clinical 
research and start to produce psilocybin in 1960. Their pill formulation contains 2mg of pure 
psilocybin and is sent to voluntary psychiatrists and psychologists (Erowid, 2019). 
A poorly supervised research phase was begun with various applications, ranging from self-
administration by psychiatrists in order to familiarize themselves with a possible model of 
psychosis, to the conducting of psychedelic-assisted psychotherapy sessions, with the aim to 
solve psychological problems such as depression. 
Unfortunately, the lack of a rigorous scientific framework in these researches, the misuse of 
these substances by the “beat generation”, as well as unsuccessful experiments conducted by 
the CIA for making a military use out of them, caused the cessation and prohibition of 
psychedelic research around 1977 all over the world (Erowid, 2019). 
It has been necessary to wait until the end of the 90s for research on psychedelics to start 
again, though timidly (Erowid, 2019) and much longer –until around 2016– to see the 
foundation of research centers specifically dedicated to psychedelic research. some of these 
centers are: The Heffter Research Institute, Beckley’s foundation, the Psychedelic Research 
Center of the prestigious Johns Hopkins University in Baltimore, founded in September 2019, 
that of Imperial College of London at the same period, but also the companies Compass 
Pathways and Usona institute (which are supported by major global health funds and 
empowered to conduct multicentric phase 2b clinical trials) or the European Foundation for 
Psychedelic Science: MIND foundation, based in Berlin and founded in 2016, which is about 
to conduct the second largest study in the world to assess the efficacy of psilocybin against 
depression this year. 
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Contemporary research: proof of concept, clinical efficiency, 
applications 
The enthusiasm expressed by these pioneers for this class of molecules has ultimately 
appeared to be justified: recent research on psilocybin demonstrates clinical interest in the 
treatment of depression, addictions, and anxiety. Psychedelics could also help in the more 
general aim of bringing a better understanding of cognitive functions and several pathologies, 
such as bipolar disorders or schizophrenia. 
In fact, despite the recent revival of psychedelic research, promising examples already exist: 
Ross and colleagues conducted a trial in 2016 to assess the efficacy of psilocybin in 29 
patients with life-threatening, cancer-related depression and anxiety. 
This randomized, placebo-controlled, double-blind study, included cancer patients who met 
DSM-IV criteria for anxiety or depression were administered either psilocybin at a dose of 0.3 
mg/kg or niacin at a dose of 250mg (the latter being administered as an active control, for the 
physical rush it provokes). 
A cross-over between the two sessions took place seven weeks after the first session. 
The primary outcome of this study was to measure anxiety and depression before crossover. 
Secondary outcomes measured before and after the crossover included: depression score 
evolution, the measurement of existential distress, quality of life and spirituality, but also the 
measurement of the immediate and persistent effects of psilocybin on subjective experience, 
cognition, affects and behavior. 
Depression and anxiety levels were assessed using internationally recognized rating scales 
such as HADS (hospital anxiety and depression scale), STAI (Spielberger straight trait anxiety 
inventory) or BDI (Beck depression’s inventory). 
Results after the first session for the “psilocybin first” group of patients showed an immediate 
and significant response for depression and anxiety. 
These results were found to remain significant at all follow-up points, including six months 
after the active session. 
The group receiving Niacin before the crossover, as expected, did not show any significant 
improvement whether it was durable or not. 
However, after the second session –the session distributing psilocybin for the patients in this 
treatment group–, as for the “psilocybin first” group, significant response rates were observed 
for depression and anxiety, and remained present even six months after the dosing session. 
About the safety of use, no serious adverse events, either psychiatric or medical, have been 
reported regarding Psilocybin. 
No psychiatric intervention (such as benzodiazepines administration) was necessary and no 
patient abused or became addicted to psilocybin (Ross et al., 2016). 
Only minor, tolerable and transient anxiety states have been reported and are not necessarily 
considered to be a negative outcome, in the sense that they would, in fact, be part of the 
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patient’s path towards their personal problems and would therefore be linked with treatment 
efficacy (Swift et al., 2017 ;  Belser et al., 2017). 
Concerning biological monitoring (blood pressure and heart rate) there was an increase in 
both these markers, but these were transient and not serious, and correspond to known effects 
of psilocybin (Ross et al., 2016). 
These results are in line with the study conducted by Krebs and Johansen in 2013, based on 
data from the national survey on drug use and Health from 2001 to 2004, which found no 
association between the use of psychedelics and any increased rate of mental illness 
(psychosis, schizophrenia, HPPD, etc.). “Magic mushrooms” have also been shown to be the 
safest drug for recreational use in the 2017 Global Health Survey, the largest study realized on 
the subject (Winstock et al., 2017). 
Another randomized double-blind study, considered to be the most rigorous to date about this 
topic, was carried out by Griffiths and colleagues in 2016 on 51 patients, with the same 
primary outcome. This time, it compared a therapeutic dose of psilocybin (22 or 30 mg/70kg), 
to a dose considered to be inactive and used as a placebo (1 or 3 mg/70kg). 
The study design was similar to the study previously presented in this review, with two 
crossover sessions, and used the same scales to assess depression and anxiety, with the 
additional use of the GRID-HAM-D (GRID-Hamilton Depression) scale for depression and 
HAM-A  (GRID-Hamilton Anxiety) for anxiety. The results of this study were found to 
confirm results observed in the trial realized by Ross and his team. 
Indeed, no medical intervention was necessary on the physical or psychiatric level during or 
following the sessions and no adverse events or addiction were to be deplored. Only transient 
anxiety was reported, as well as headache, during or after the high-dose session, in few 
participants (Griffiths et al., 2018). 
From an efficacy point of view, again, the group that received a high dose of Psilocybin first 
showed a 92% response rate (32% in the “low dose first” group) and these results were still 
observable after 6 months in 80% of the patients in this group. 
On the HAM-A scale, the results were 76% for response rate (versus 24% in the control 
group) and 83% at 6 months. After merging the results of the two sessions, response rates for 
depression and Anxiety were 78 and 83% respectively and remission rates were 65% and 
57%, respectively (Griffiths et al., 2018). 
The results of these two studies are very encouraging. Thereby, they were the subject of a 
meta-analysis that also presented two further qualitative studies on patients’ experience with 
psilocybin. The meta-analysis aimed to ensure that the results obtained were statistically 
significant when compared to placebo and when combining the results of the two studies, 
thanks to the use of a Peto ODDS ratio (Figure 1) (Bahi, 2018). 
The results obtained with the psilocybin group were found to be significantly and largely 
superior to the results obtained for the placebo group. 
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Phase 2b clinical trials are currently underway intending to use psilocybin in treatment-
resistant depression. The companies Compass Pathways and Usona institute have received the 
“breakthrough therapy” status from the FDA for studies on this application. The MIND 
foundation is expected to start the second largest study in the world to assess the efficacy of 
psilocybin against depression around summer 2020. 
Other fields of application are envisaged, like the treatment of addictions; in this line, Johns 
Hopkins University is launching a clinical trial with the aim of treating nicotine-addicted 
patients in 2020 (Johns Hopkins University, 2019). 
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Figure 1.  Psychedelics show a significantly better response rates on 
depression and anxiety compared to placebo. 
(Bahi, 2018)
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Mechanism of action 
The efficacy of these potential treatments in depression is therefore firmly assessed, and they 
are on their way to obtaining a market authorization in the upcoming years; however, the 
mechanisms underlying their effect have not yet been fully elucidated. 
Research on this topic shows an increase in neuronal plasticity probably involving an increase 
in the level of neurotrophic factors such as BDNF, as well as modification of the connectivity 
in neural networks involved in resting-state activity, such as the DMN or default mode 
network, which is physiologically responsible for high-level cognition functions such as 
introspection and rumination (the latter being more specific to MDD) and is mainly implying 
an anteroposterior functional and blood coupling between the PCC (posterior cingulate 
cortex), the mPFC (medial prefrontal cortex) and the amygdala (Carhart-Harris et al., 2016). 
Several articles highlight the fact that these changes in structural plasticity and functional 
connectivity within networks could be linked and superposed to the behavioral improvements 
associated with treatment response (Carhart-Harris and Nutt, 2017; Ly et al, 2018). This review 
will focus on exploring this link. 
Furthermore, it is interesting to note that connectivity changes in these resting-state networks 
are implied in other therapies previously mentioned, such as ketamine, but also in tDCS 
(transcranial direct current stimulation) and electroconvulsive therapy (Woelfer et al., 2019; 
Keezer et al., 2011; Carhart-Harris and Nutt, 2017). 
Other researchers highlight the specificity to which the action of psychedelics is subject 
through 5HT2A agonism, by demonstrating that the blockade of these receptors by a specific 
antagonist such as ketanserin, both abolishes the hallucinogenic effect in humans and the 
effect on in vitro neuronal plasticity mediated by these molecules (Ly et al., 2018; Preller et 
al., 2019). 
Moreover, we now know that 5-HT2AR agonist action positively modulates glutamatergic 
neurotransmission (figure 2) and activates signaling pathways involving B-arrestine, for 
example (Vollenweider and Kometer, 2010), a protein engaged in neuronal plasticity 
pathways such as the mTOR signaling pathway (Jean-Charles et al., 2017). 
12 Figure 2. Activation of the prefrontal network and glutamate release by psychedelics  
(Vollenweider and Kometer, 2010)
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Unraveling implied mechanisms: from molecular targets to 
network connectivity. 
A common signaling pathway shared by psychoplastogens, also 
involved in functional connectivity changes? 
Exploring signaling pathways 
As discussed above, one of the key mechanisms involved in the effect of psychedelics 
depends on their 5HT2A-R agonism properties, causing a hallucinogenic effect, which is 
involved in their efficacy against depression (swift et al., 2017; Davis et al ., 2020; see Bahi, 
2018 for review). 
This property would also underlie the overexpression of neurotrophic factors such as BDNF, 
as well as changes in the activity and connectivity within several resting-state functional 
networks (i.e. engaged when no specific task is proposed during functional MRI). 
These two last points seem to be necessary for psychedelics’ immediate and long-term 
efficacy. 
These arguments are reinforced by the fact that altered anteroposterior connectivity in specific 
DMN regions is often observed in MDD and is associated with the ruminative aspect of MDD 
which represents an important component of this syndrome (Carhart-Harris and Nutt 2017). 
To verify that the neuroplasticity occurring following the use of psychedelics is linked with 
their 5-HT2AR agonist properties and to get a closer look at the signaling pathways that 
underlie this mechanism, Ly’s team carried out a series of experiments based on results 
observed with ketamine. 
Results confirm the initial hypothesis: the psychedelic molecules tested were able to increase 
arbor complexity  in rats’ cortical neurons, showing an increase in the number of dendrites’ 
branches and also an increase in the total length of the arbor, without however causing an 
increase in the number of primary dendrites, nor the size of the longest dendrites. 
7,8- dihydroxyflavone (DHF) was used as a positive control because of its well-known 
plasticity-promoting properties and its different structure and molecular target compared to 
psychedelics. This control is also able to promote complexification of the arbor, while 
negative controls such as Serotonin or D-Amphetamine are not. 
Then, Ly’s team determined the relative potency in plasticity induction using an 8 points 
dose-response study with an effect varying from 0 to 100%, with 0% being defined by the 
effect of the vehicle (DMSO, which is a solvent) at a concentration of 0.1%, and 100% being 
defined by a 10umol Ketamine concentration (corresponding to the maximum brain 
concentration obtained after an intraperitoneal injection of Ketamine in rats). 
Surprisingly, psychedelics constantly showed better results than ketamine at the same dose. 
These results were verified in vivo, using Drosophila Larvae as an experimental model and 
LSD (ergot-derived psychedelic molecule) and DOI (which has an amphetaminic structure) as 
the active molecules (Ly et al., 2018). 
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Again, the number of dendritic branching in class 1 sensory neurons was found to be 
increased, without however observing an increase in the total length of dendritic arbors. 
These results, confirmed in both vertebrates and invertebrates, suggest that the mechanism 
underlying this plasticity promoting abilities is evolutionarily conserved (Ly et al., 2018). 
Dr. Ly and colleagues then wanted to assess the effects of psychedelics on synaptogenesis and 
spinogenesis in rats. They proceeded in vitro first, by exposing rat cortical neurons to DOI, 
DMT (tryptamine psychedelic) and LSD, and in vivo afterward, with a 10mg/kg DMT 
peritoneal injection. Results demonstrated an increase in the synapse density and an increase 
in the number of dendritic spines (up to 2 times more spines), without however showing any 
change in the dendrite length in vitro (figure 3). 
In vivo, these results were mainly observable on pyramidal cortical neurons (which is also the 
preferred localization for 5HT2A receptors in the cortex) and with an intensity comparable to 
standards results observed with Ketamine at the same dosage (Ly et al., 2018). 
It is important to note that these remarkable effects on structural neuroplasticity were 
accompanied with changes at the functional level in the PFC: similar increases in the 
amplitude and frequency of spontaneous excitatory postsynaptic currents (EPSCs) were 
observed at both 10mg/kg and 1mg/kg concentrations (hallucinogenic and sub-hallucinogenic 
doses). 
Furthermore, the fact that the half-life of DMT is only 15 minutes and that the functional 
changes were still observable hours after this delay, seems to indicate that the plasticity 
promoting abilities of psychedelics can last after total clearance of the substance from the 
body (Ly et al., 2018). 
These changes also mirror those produced by Ketamine (Li et al., 2010). This underlines an 
additional parallel between psychedelics and Ketamine: indeed, these two classes of 
psychoplastogens seem able to cause similar plasticity changes both at the structural and 
functional levels in an immediate and lasting way. These two types of substances are also able 
to facilitate fear extinction learning, a behavioral mechanism involved in stress response 
(Cameron et al., 2018; Girgenti et al., 2017), in which the PFC is predominantly involved 
(Quirk et al., 2006). 
In addition, fear extinction learning can be improved by increasing BDNF concentration in 
the PFC and the behavioral effects of Ketamine have been shown to be BDNF-dependent 
(Lepack et al., 2014). 
The role of neurotrophic factors in neuroplasticity is well established today (Cohen-Cory et 
al., 2010) and various studies have shown that psychedelics may be able to increase the levels 
of neurotrophic factors, especially BDNF (He and al., 2005; Martin et al., 2014; Nichols and 
Sanders-bush, 2002, Vaidya et al., 1997). 
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Figure 3. Psychedelics Promote Spinogenesis, Synaptogenesis, and Functional Plasticity  
(A) Representative images of cortical neurons (DIV19) treated with compounds for 24h, demonstrating that 
psychedelics increase the number of dendritic spines (blue, MAP2; orange, F-actin). 
(B) Quantification of spine density (n = 56–65 neurons). 

(C) Relative proportions of spine types following treatment of cortical cultures with psychedelics (n = 16–21 neurons). 
(D) Representative images of cortical neurons (DIV19) treated for 24 hr, demonstrating that psychedelics increase 
synaptogenesis (green, VGLUT1; magenta, PSD-95; yellow, MAP2). White areas in the VGLUT1 + PSD-95 images 
indicate colocalization of pre- and postsynaptic makers and are indicated by gray arrows. 
(E–H) Quantification of synapse density (E), synapse size (F), presynaptic density (VGLUT1) (G), and postsynaptic 
density (PSD-95) (H) following 24-hr treatment of cortical neurons (DIV19) (n = 39–42 neurons). 
(I) Representative images of Golgi-Cox-stained pyramidal neurons from the PFC of rats 24 hr after receiving a 10 mg/
kg dose of DMT. 
(J) Quantification of spines from (I), demonstrating that DMT (10 mg/kg) increases spinogenesis in vivo to a 
comparable extent as ketamine (10 mg/kg) (n = 11–17 neurons). 
(K and L) Whole-cell voltage-clamp recordings of layer V pyramidal neurons from slices obtained 24 hr after DMT 
treatment (10 mg/kg and 1 mg/kg) demonstrate that DMT increases both spontaneous excitatory postsynaptic 
current (sEPSC) frequency (K) and amplitude (L) (n = 11–38 neurons from 3 animals). 
(M) Representative traces for the 10 mg/kg experiments quantified in (K) and (L). 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control (VEH). Data are represented as 
mean ± SEM. See also Figure S6. 

(Ly et al., 2019)
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It is therefore natural that Ly’s team sought to determine the link between BDNF and 
psychedelics’ ability to promote structural and functional plasticity. 
To verify it, they first treated rat cortical neurons with BDNF, DOI (10um) and a combination 
of the two, in order to explore if there was a possible synergistic or additive effect: 50 mg/mL 
BDNF increased spinogenesis and synaptogenesis to a comparable extent as 10uM DOI. 
Moreover, a combination of the two substances did not confer any benefits to neuroplasticity 
(Ly et al., 2018). This implies that the mechanism promoting neuroplasticity mediated by 
these two substances is in fact shared. 
Cultured neurons were then treated with psychedelics (DOI, LSD, DMT) for 24 hours to 
monitor BDNF gene and protein expression. 
No changes in gene transcripts were observed. However, BDNF protein levels were two times 
higher. This increase was not significant, but blockade of BDNF’s high-affinity receptor Trkb 
with the high-affinity antagonist ANA-12 completely abolished any BDNF or psychedelics 
effects on synaptogenesis or spinogenesis (Ly et al., 2018). 
Since Trkb receptor activation leads to mTOR signaling (which is essential for promoting 
neuronal plasticity and neurotrophic factors production) and that the response to Ketamine is 
dependent on this pathway, Ly and colleagues decided to treat cultured neurons with 
Rapamycin, a specific mTOR inhibitor, to find out whether it was involved in plasticity 
mediated by psychedelics. 
Without surprise, psychedelic-induced neuroplasticity was completely blocked following 
Rapamycin exposure. These results confirm that mTOR pathway plays a decisive role in the 
plasticity promoted by psychedelics (Ly et al., 2018).  
By specifying the signaling pathways involved in the plasticity promoting properties of 
psychedelics, these results bring further details to Vollenweider and Kometer’s hypothesis 
formulated in 2010, suggesting a shared mechanism of action between Ketamine and 
psychedelics underpinning their efficacy in depression (Figure 4). 
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Figure 4. Ketamine and Psychedelics action on depression through mTOR 
(According to Réus et al., 2015) 
Psychedelics 
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Lastly, Ly and colleagues aimed to verify that the plasticity-promoting proprieties of 
psychedelics was indeed caused by 5HT2A receptors’ stimulation (since this stimulation is 
also responsible for the hallucinogenic effect, that their psychoplastogen proprieties are 
strongly correlated to their affinity for these receptors and that these receptors do not 
constitute a target for Ketamine, which appears to share the same signaling pathways). 
The researchers verified first that cultured cortical rats’ cells were indeed presenting 5HT2A 
receptors and then treated those cultures with psychedelics. 
Then, they noted that blocking those receptors with a specific agonist: Ketanserin, at a 100-
fold concentration compared with psychedelics (the concentration which induced the maximal 
effect in normal condition: 10Um) resulted in a complete blockade of the plasticity promoting 
proprieties of psychedelics tested (Ly et al., 2018). 
It is, however, possible that Ketanserin blocked other receptors at this concentration. To limit 
this possible bias, they used lower doses of LSD (10nM) and progressively increased the 
associated Ketanserine dosage (Ly et al., 2018). At a dose of 10nM, Ketanserin was able to 
block 50% of LSD’s psychoplastogenic effects for 10 nM, which is in line with the fact that 
these two molecules have a similar affinity for 5HT2A-R. 
Accordingly, 100nM doses of Ketanserin were able to completely block the effect of 10nM 
LSD concentrations. At this dose, Ketanserin is a fairly specific 5HT2A-R antagonist (Ly et 
al., 2018). 
These results prove the direct implication of psychedelics in plasticity promotion and give 
further details about their precise mechanism of action, mediated by 5HT2A-R and implicated 
in their efficacy against depression. 
Ly’s experiments also reveal that molecules with different structures (tryptamines, ergolines, 
amphetamines) and different molecular targets (Ketamine block NMDA-R while psychedelics 
stimulate 5HT2A-R) are sharing the same signaling pathways (involving BDNF, Trkb and 
mTOR) underlying their plasticity promoting properties. This is even more remarkable since 
Ketamine can lead to addiction, whereas psychedelics do not (Nutt et al., 2007, 2010) and that 
these effects are consistent both in vitro and in vivo, with species of different degrees of 
evolution. 
Another notable element is that the activation of these neuroplasticity pathways seems to 
mediate the behavioral effects associated with the response to these substances through 
network connectivity changes. The amplitude of these changes seems to correlate with the 
psychoplastogenic potency of these substances (Ly et al, 2018). 
This last point is particularly important for establishing the link between the molecular targets 
that promote neuroplasticity and associated functional connectivity changes in functional 
brain networks implied in depression (the focus point being on the  DMN, whose functional 
connectivity changes are involved in psychedelic and Ketamine antidepressant responses 
Carhart-Harris et al., 2016, Kraguljac et al., 2017; Woelfer et al., 2019). 
Similar functional connectivity changes within the DMN are also observed using non-
pharmacological techniques, such as ECT or tDCS, and seem to be correlated with the 
behavioral response to these therapies (Carhart-Harris and Nutt, 2017; Keeser et al., 2011). 
Nevertheless, the precise origin of these functional changes in resting state networks remains 
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poorly understood. Specifying these pathways could then also be useful outside psychedelic 
therapy and even pharmacological therapies framework. 
             Exploring mechanisms underlying functional connectivity changes. 
Some research about Ketamine that has explored the origin of these resulting functional 
connectivity changes could also apply to psychedelics. 
Researchers underline that the increase of peripheral BDNF levels correlates with functional 
connectivity changes observed after Ketamine infusion in a placebo-controlled, double-blind 
study carried out on 53 healthy volunteers by Woelfer and colleagues in 2019. 
This study aimed to explore and assess this eventual correlation. They proceeded by 
collecting a blood sample in patients at three time points (before Ketamine infusion, 120 
minutes and finally 24 hours after infusion), quantifying BDNF levels in these samples using 
the sandwich ELISA immunoenzimatic technique, and comparing this variation in plasma 
BDNF levels with the functional connectivity changes observed in brain areas that are known 
to show modified connectivity after Ketamine, using RS-fMRI (Woelfer et al, 2019). 
Those regions include structures such as the mPFC and Posterior Cingulate Cortex, that 
superpose with the Default Mode Network and correspond to the structures where the 
functional connectivity is modified during psychedelic infusion (Carhart-Harris et al., 2016).  
Statistical correlation analyses between these data were then carried out to verify the initial 
hypothesis: As expected, results showed a significant correlation between the variation in 
peripheral BDNF levels and changes in functional connectivity in the DMN for patients in 
whom Ketamine infusion led to an increase in BDNF levels. This correlation is particularly 
significant when looking at the disconnection between PCC and mPFC occurring during the 
effect of Ketamine (Woelfer et al, 2019). 
On the other hand, the placebo group and patients whose BDNF levels were not increased 
following Ketamine infusion did not show any correlation between functional connectivity 
and variation in BDNF levels over 24 hours. These results support the hypothesis according to 
which a proportionality relation exists between BDNF overexpression and changes in 
functional connectivity, as well as the hypothesis according to which the response to 
Ketamine (and, supposedly, psychedelics) in depression might depend on the amplitude of 
BDNF overexpression in patients (figure 5) (Woelfer et al., 2019). 
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Figure 5. Whole-brain regression analysis with interaction term to test 
the link between BDNF and resting-state functional connectivity (RSFC) 
changes at 24 h post-infusion.  
(A) Participants receiving ketamine or placebo showed a significantly 
differential association between changes in plasma BDNF levels after 
24 h compared to baseline and dorsomedial prefrontal cortex 
(dmPFC) seeded RSFC changes to ventromedial prefrontal cortex 
(mPFC), posterior cingulate cortex (PCC), right superior temporal 
gyrus (STemp), left inferior temporal gyrus (ITemp) and cerebellum at 
24 h compared to baseline (p < 0.05 FWE, n1⁄453; x and z represent 
MNI coordinates). Scatter plots depict link between plasma BDNF 
levels and RSFC changes after 24h compared to baseline divided by 
subgroups for (B) mPFC and (C) PCC after ketamine (left side) and 
placebo (right side) infusion. Data points above the horizontal 
reference line at zero represent subjects from subgroups with an 
increase in BDNF levels after ketamine or placebo infusion, whereas 
data points below the horizontal reference line represent the 
subgroups with a decrease in BDNF levels. Crosses represent the 
mean and the standard error of mean (SEM) of the subgroups and 
the whole group (in black, n1⁄453). Dotted vertical lines represent the 
borders when RSFC changes become significant for the whole 
group. 

(Woelfer et  al., 2019)
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The fact that BDNF levels are statistically correlated with a decrease in the connectivity 
between the PCC and mPFC inside the DMN highlights the similarities existing between 
Ketamine and psychedelics, provoking similar changes in the DMN, BDNF expression and 
structural plasticity. Therefore, it would be interesting to assess if this correlation between 
BDNF levels and RSFC’s changes could be observed for psychedelics as well. 
Furthermore, Woelfer and colleagues suggest that changes in functional connectivity could be 
depending on mTOR pathway activation occurring after BDNF binding on Trkb, leading to an 
improvement in glutamatergic transmission (Li M et al., 2018; Kraguljac et al., 2017). 
This pathway is actually the one that has been shown by Ly and colleagues to be shared by 
both psychedelics (5-HT2A receptor agonists) and Ketamine (NMDA receptor antagonists), 
providing their plasticity-promoting proprieties.  
  
The results of these two studies shed light on the hypotheses put forward by Vollenweider and 
Kometer in their review about neurobiological mechanisms involved in psychedelics action 
(Vollenweider and Kometer, 2010) by specifying the precise pathway shared by Ketamine and 
psychedelics to promote structural but also functional plasticity. They also bring some 
preliminary details about its role in the behavioral response associated with these substances. 
From structural and functional plasticity to psychological flexibility? 
According to Carhart Harris and Nutt, two types of mechanisms (neurobiological and 
psychological plasticity) that can be observed in psychedelics’ antidepressant response could, 
in fact, be linked (as previously examined research on ketamine suggests too), and the short 
and long-term antidepressant action of psychedelics appear to be dependent on this 
phenomenon (Carhart-Harris and Nutt, 2017; Swift et al .,2017; Belser et al., 2017; Davis et 
al., 2020). 
Carhart-Harris and his team have also developed a brain functioning model to explore this 
link, called “the entropic brain” model (Carhart-Harris et al., 2014), and applied it to MDD 
major depressive disorder in their article “Serotonin and brain function, a tale of two 
receptors” published in 2017. This model is based on brain imaging sessions carried out 
during and after the psychedelic experience. According to this model, what we observe on 
RS-fMRI (resting-state fMRI) on the neurobiological level, during and after the infusion of 
psychedelics, correspond and superpose to the behavioral effects of these substances on 
depression, and reciprocally. 
To introduce this hypothesis, the research team recalls that entropy (a concept that is usually 
applied in thermodynamics) can be defined as the uncertainty and unpredictability of events 
in a system (Ben-Naim, 2007), and has both a mechanical and perceptual meaning.  
Indeed, depressed patients often present a state of mental rigidity (Holtzheimer and Mayberg, 
2011), characterized by anhedonia, pessimistic-oriented cognition, and disconnection from 
emotions (Berman et al., 2011; Holtzheimer and Mayberg, 2011). 
In addition, as described above, low levels of neurotrophic factors have been found in 
depressed patients, as well as deleterious changes in connectivity (rigid reinforcement in 
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certain resting state networks, particularly within the DMN). All these arguments are in line 
with a lowered brain entropy, according to the model presented by Carhart-Harris and Nutt. 
Conversely, patients who have received a psychedelics infusion express a sense of liberation, 
the feeling of having been “reset”, reconnecting with their emotions and a better acceptance 
towards it (Turton et al., 2014; Watts et al., 2017; Roseman et al., 2017b, Bahi 2018, Davis et 
al., 2020, Swift et al., 2017). These elements are consistent with a more flexible, plastic, 
emotional state. At the same time, beneficial functional modifications are observed within 
resting state networks and an increase in neurotrophic factors expression, like BDNF, are also 
notified: These states correspond to a restored or even increased brain entropy according to 
the model presented by Carhart-Harris and Nutt. 
To further assess this hypothesis, Carhart-Harris’s team set out to measure the variance in 
functional connectivity patterns in several identified neural networks, during a psychedelics 
infusion. 
Cerebral entropy measurements inspired by the “free energy principle” by Karl Friston 
(Friston 2010) were then carried in 9 canonical networks, including the DMN, during 
Psilocybin or placebo intravenous infusion: 
The measurement of entropy within neural networks was carried out in a placebo-controlled 
clinical trial, on 15 healthy volunteers. An intravenous psilocybin or placebo infusion was 
delivered for 60 seconds, halfway through two 12-minutes bold fMRI brain imaging sessions 
with eyes closed, on different days. 
To estimate this entropy, the researchers first measured the variance in the state of synchrony 
within different networks: if the signal between all the voxels of a given network deviated 
very little compared to the global signal, then the variance was considered low within this 
network; if the signal of the network deviated erratically and significantly, then the variance 
was considered high within this network.  
During the psilocybin infusion, the variance was increased within the networks associated 
with high levels of cognition, but not in the networks associated specifically with sensory or 
motor activities. No significant change was found during the placebo sessions. 
These results are consistent with the entropic brain model (Carhart-Harris et al., 2014). 
Carhart-Harris’ team then sought to express these results as a formal measure of entropy, by 
calculating the probability distribution of the variance of the intra network synchrony across 
time: They discretized the time course of intra-network synchrony over time in virtual equal-
sized bins and each time point was entered into a bin depending on the variance in the 
network synchrony at that time point. Then, Shannon’s entropy was calculated for each 
network (Carhart-Harris et al., 2014). 
As expected, results showed that there was a significantly greater entropy in the high-level 
association networks too, particularly within the DMN (Figure 6, Carhart-Harris et al., 2014). 
Moreover, the connectivity patterns of the network during psilocybin infusion were 
significantly more random and unpredictable than those observed with placebo (Carhart-
Harris et al., 2014). 
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Figure 6. Changes in network metastability and entropy post-infusion of psilocybin.  
(A) This chart displays the mean variance of the internal synchrony of 9 brain networks for the sample of 15 healthy volunteers, as a 
percentage change post vs. pre-infusion. A post-infusion increase in metastability for a specific network indicates that the mean signal 
in that network is a poor model of the activity in its constituent voxels, implying that the network is behaving more “chaotically” post-
infusion than pre. Bonferonni correction gave a revised statistical threshold of p < 0.006 (0.05/9). One-sample (2-tailed) t-tests were 
performed, comparing the % change against zero. The significant networks are labeled with an asterisk. 

(B,C) These probability distributions were derived from data from the same single subject, by discretizing a measure of the internal 
synchrony of the DMN across time into bins. These bins reflect the distance a data point is from the mean and this gives a probability 
distribution of the variance of internal synchrony within a network for a given time period (e.g., a 5min period of scanning). The 
probability distributions shown in Chart B were produced from placebo data where it is clear that prediction of internal network 
synchrony of the DMN across time is similar before and after infusion (i.e., the blue and green curves). The probability distributions 
shown in Chart C were derived using psilocybin data and here it is evident that following infusion of psilocybin (i.e., the green curve), 
prediction of internal network synchrony within the DMN is more difficult compared to pre infusion (the blue curve). When the entropy 
change was calculated for the group, significantly greater increases in entropy were found in the same networks highlighted in (A) 
(post-psilocybin vs. pre) vs. (post-placebo vs. pre). 

(Carhart-Harris et al, 2014)
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When applied to the “entropic brain” model, these results suggest that 5HT2A receptors 
stimulation could constitute a way to increase brain entropy, through disintegration and 
reintegration of particular resting-state networks, such as the DMN.  
To go further assessing a specific pathway connecting molecular, connectivity and behavioral 
aspects of the psychedelics’ mechanism, and using the results of the studies presented earlier, 
it may be suggested that this increase in entropy within specific brain networks could be 
linked to the action of BDNF and mTOR pathways: this process would then promote a more 
flexible and plastic state, at a neurobiological, but also at a cognitive and behavioral level, 
thus constituting a key mechanism in psychedelics’ effectiveness against MDD. 
Therefore, this could allow a “reset” in the psychological mechanisms reinforced during the 
onset of major depressive disorder that led the patient to this state of rigidity –depicted by a 
pessimistic vision of himself and his environment (Moutoussis et al., 2014)– and reduced the 
ability to cope with personal difficulties.  
The notion of network reinitialization is also explored through similarities between acute 
functional connectivity changes observed over 24h with both psilocybin and ECT (Carhart-
Harris and Nutt, 2017). 
This reset then favors a more malleable and flexible cognition, allowing the patient to benefit 
more fully from psychological and cognitive therapies, giving him the possibility to get out of 
his pessimistic perceptions and take advantage of his personal difficulties, receiving the 
benefits that these life events could provide. 
Through this process, mental rigidity is then alleviated, in favor of flexibility and plasticity, 
due to a mechanism that could be compared, according to the analogy developed by Carhart-
Harris, to the one that allows an apparently inflexible metal piece to be shaped by heating it, 
increasing the entropy within it, allowing it to become malleable (Carhart-Harris and Nutt, 
2017). 
  
A study that has been recently published (January 2020) conducted by Davis and colleagues at 
the Johns Hopkins University also adds weight to this hypothesis. 
This study was conducted on 985 volunteers who used psychedelics during their lifetime and 
was carried out in the format of an online survey, to explore a possible correlation between 
the acute effects of psychedelics and an increase in psychological flexibility, as well as 
between an increase in psychological flexibility and a decrease in anxiety and depression 
scores (Davis et al., 2020).  
 DASS-21 (depression, anxiety and stress scale) was used to measure the corresponding 
factors and the Acceptance and Action Questionnaire 2 (AAQ-2) was expressed in positive 
values to measure the psychological flexibility. 
MEQ30 mystical experience scale and Psychological Insight Questionnaire (PIQ; that was 
created for this purpose) were also used to explore a possible correlation between the increase 
in psychological flexibility, the occurrence of mystical experience and “psychological insight” 
(Davis et al., 2020). 
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Results show a significant correlation between the acute effects of psychedelics, an increase 
in psychological flexibility, reduction in depression and anxiety scores, and verify the 
statistical hypotheses according to which:  
“acute psychedelic effects (mystical and insight effects) predict a decrease in depression and 
anxiety following a psychedelic experience” (H1), “acute psychedelic effects predict the 
increase in psychological flexibility in patients” (H2), “the increase in psychological 
flexibility predicts a decrease in depression and anxiety scores” (H3) and finally, “the increase 
in psychological flexibility represents a mediator between Psychedelics acute effects and the 
decrease in depression and anxiety associated with these substances” (H4) (figure 9) (Davis et 
al., 2020). 
These results need to be verified in laboratory settings and on a more diversified sample of 
patients, but they already give a concrete psychological appreciation of the hypothesis 
formulated by Carhart-Harris, by quantifying and assessing the development of psychological 
flexibility after psychedelics’ administration, which is beneficial in reducing depressive and 
anxious symptoms. 
Finally, to further support the global model suggested in this review, it is relevant to specify 
that Wolff and colleagues proposed a psychological model underlying this increase in 
psychological flexibility. This model suggests that the psychedelic experience could promote 
acceptance over aversion based coping methods and involves fear extinction learning as well 
as beliefs-relaxation (Wolff et al., 2020). This theory is in line with the hypothesis formulated 
by Ly and colleagues, linking the neurobiological and pharmacological effects of psychedelics 
to their behavioral outcomes through fear extinction learning, but also add a cognitive 
explanation to the entropic brain model and the associated psychological flexibility that it 
involves by linking increased entropy to beliefs-relaxation. 
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Figure 9. Path analysis showing that increases in psychological flexibility mediate relationship between acute effects of psychedelics and 
decreases in depression/anxiety (full sample, N=985). **p<.01, ***p<.001. 
(Davis et al., 2020)
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Conclusion 
This review presents several limitations that need to be discussed:  
Firstly, it explores an innovative direction regarding what is known and done about major 
depressive disorder, focusing on signaling pathways that have been little envisaged so far and 
for which precise mechanisms remain unclear. Moreover, all the results from the articles 
exposed in this review remain to be reproduced on a larger number of patients, and some need 
to be confirmed in a human model. 
Several studies also require to be reproduced in patients with depression, such as the study 
conducted by Woelfer and colleagues, exploring the correlation between peripheral BDNF 
evolution and changes in functional connectivity after Ketamine infusion. It is important to 
note that, although the peripheral BDNF levels are correlated to the central levels, knowledge 
about BDNF remains incomplete. This is also the case for the study conducted by Carhart-
Harris et al., presenting the cognitive model “the entropic brain” applied to depression. 
In addition, it is possible to criticize this review for being reductive in its approach: exploring 
the role of neuroplasticity in depressive disorder, by connecting the effects of psychedelics on 
structural and functional plasticity to their psychopharmacological mechanisms (involving 5-
HT2A signaling, BDNF –mostly cortical– and mTOR pathway) and to the behavioral and 
psychological manifestations superposing to these functional changes. 
Indeed, this approach –despite holding a central position among the pathophysiological and 
clinical aspects of depression– does not take into account the full complexity of this pathology 
and the broad range of mechanisms that it implies.  
However, this perspective could be useful in the sense that it gives place to isolate and 
highlight some mechanisms that can serve both as potential targets in the framework of 
depression treatment, as a starting point for developing more therapeutic tool against this 
pathology as well as a way to develop biomarkers in psychiatry (e.g. for antidepressant 
response). It also gives further details about several hypotheses formulated several years ago, 
concerning psychedelics’ mechanism of action (Vollenweider and Kometer, 2010). 
These steps are important for allowing the development of new and effective ways to fight 
depression, a process that has been slowed down for years. 
Another limitation in this review is that it relies on connections established between the 
molecular, functional and psychological levels, which are based on correlations and 
similarities between different therapies, but it is too early to establish the existence of a direct 
causal link. 
Indeed, the mechanism put forward by Woelfer and colleagues underlying the increase in 
peripheral BDNF levels and changes in functional connectivity after Ketamine infusion is still 
unclear and its possible application to Psychedelics remains to be confirmed, although several 
arguments support this hypothesis (e.g. the fact that they share the same signaling pathways 
for promoting plasticity). 
The correlation between functional changes and psychological improvements must also be 
rigorously explored and this task could be complex, from a methodological point of view. 
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This endeavor could nevertheless reveal crucial information concerning the role of BDNF and 
mTOR signaling pathway in the behavioral aspects of major depressive disorder. 
However, this review highlights the opportunities that the study of 5-HT2AR mediated 
cerebral plasticity brings, offering important clues about the specific role that these receptors 
play in MDD. It also reveals important information about the interaction between different 
neurotransmitter systems (glutamate and serotonin), particularly through mTOR pathway 
activation via TrkB, due to an increase in cortical BDNF levels occurring after 5-HT2A 
stimulation by psychedelics. These properties appear to be shared by both 5HT2A receptor 
agonists and NMDA receptor antagonists. 
This pathway promotes structural neuroplasticity, but also seems responsible for functional 
connectivity changes in resting state neural networks involved in depression. 
These functional and structural plasticity changes appear to constitute a neurobiological 
support that superposes with the behavioral improvements associated with the antidepressant 
response provided by psychedelics. 
Connecting these dots could furthermore provide tracks to clarify the mechanisms of action 
possibly shared by several non-pharmacological techniques such as neuromodulation (e.g. 
ECT, tDCS) or even mindfulness meditation techniques. 
Through the exploration and connection of these mechanisms, this review partially lifts the 
veil that obscures the question of the neurobiological support underlying the efficacy of 
substances that have long been “controversial”, against MDD.  It also highlights the 
advantage of having a transdisciplinary and holistic view on psychiatry and major depressive 
disorder; bringing pharmacological, cognitive and psychological aspects together.  
Furthermore, this review contributes to reinforcing the legitimacy of conducting research on 
this topic, by presenting a small fraction of the great amount of fundamental and translational 
research undertaken on psychedelics and Ketamine for mental health as well as underlining 
the potential offered by these substances to get a better understanding of depression, and, 
more globally, of general brain function. 
In the future, it would be interesting to define to what extent BDNF and mTOR’s signaling 
pathway modulation (triggered by 5-HT2A-R activation and NMDA antagonism) could play 
an important role in depression.   
To make it possible, it would be pertinent to explore how the decrease in BDNF levels 
observed in both the HPA and inflammatory hypotheses could be related to the mental rigidity 
manifested by depressive patients. 
It would also be relevant to explore the apparently distinct roles of cortical and hippocampal 
BDNF in depression and how 5HT2A-R agonism leads to an overexpression of cortical 
BDNF levels. 
Studying the differences between the pathways that are seemingly shared by Psychedelics and 
Ketamine would also be a great way to develop future useful therapies, understanding, for 
instance, why Ketamine is addictive while Psychedelics are not, and then being able to target 
BDNF overexpression and mTOR stimulation using the most beneficial and safe gateway. 
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Finally, establishing which psychological and cognitive methods should be used to obtain 
maximized benefits from the psychedelic therapy is also an important concern, and 
therapeutic methods that aim to promote acceptance seem to be an interesting track to explore 
(Wolff et al., 2020). 
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